Sokkar, Pandian http://orcid.org/0000-0002-6692-7066
Harms, Mirja
Stürzel, Christina
Gilg, Andrea
Kizilsavas, Gönül
Raasholm, Martina
Preising, Nico
Wagner, Manfred
Kirchhoff, Frank
Ständker, Ludger http://orcid.org/0000-0002-8436-4260
Weidinger, Gilbert http://orcid.org/0000-0003-3599-6760
Mayer, Benjamin
Münch, Jan http://orcid.org/0000-0001-7316-7141
Sanchez-Garcia, Elsa http://orcid.org/0000-0002-9211-5803
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (CRC1279)
Article History
Received: 21 January 2021
Accepted: 31 August 2021
First Online: 22 September 2021
Competing interests
: Authors P.S., M.H., L.S., F.K., J.M. and E.S.-G. are inventors of granted or pending patents claiming to use EPI-X4 and optimized derivatives for the therapy of CXCR4-linked diseases.